Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ZYME
- Price
- 9.91
- Stock movement down
- -0.52 (-4.99%)
- Company name
- Zymeworks Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 682.58M
- Ent value
- 680.39M
- Price/Sales
- 10.97
- Price/Book
- 1.86
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 6.52%
- 1 year return
- 2.69%
- 3 year return
- 14.16%
- 5 year return
- -22.00%
- 10 year return
- -
Last updated: 2025-04-09
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ZYME does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10.97 |
| Price to Book | 1.86 |
| EV to Sales | 10.94 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 68.88M |
| EPS (TTM) | -1.49 |
| FCF per share (TTM) | -0.78 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 62.20M |
| Gross profit (TTM) | -960.00K |
| Operating income (TTM) | -121.03M |
| Net income (TTM) | -113.67M |
| EPS (TTM) | -1.49 |
| EPS (1y forward) | -1.71 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1.54% |
| Operating margin (TTM) | -194.58% |
| Profit margin (TTM) | -182.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 122.36M |
| Net receivables | 23.70M |
| Total current assets | 343.77M |
| Goodwill | 12.02M |
| Intangible assets | 6.58M |
| Property, plant and equipment | 35.69M |
| Total assets | 487.15M |
| Accounts payable | 3.42M |
| Short/Current long term debt | 20.25M |
| Total current liabilities | 83.91B |
| Total liabilities | 120.17M |
| Shareholder's equity | 366.98M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -54.31M |
| Capital expenditures (TTM) | 5.23M |
| Free cash flow (TTM) | -59.54M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -30.97% |
| Return on Assets | -23.33% |
| Return on Invested Capital | -30.73% |
| Cash Return on Invested Capital | -16.10% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.06 |
| Daily high | 11.09 |
| Daily low | 9.74 |
| Daily Volume | 941K |
| All-time high | 56.81 |
| 1y analyst estimate | 18.97 |
| Beta | 1.16 |
| EPS (TTM) | -1.49 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Apr 2025 |
Downside potential
Loading...
Downside potential data
| ZYME | S&P500 | |
| Current price drop from All-time high | -82.56% | -19.00% |
| Highest price drop | -91.81% | -56.47% |
| Date of highest drop | 7 Sep 2022 | 9 Mar 2009 |
| Avg drop from high | -50.44% | -11.07% |
| Avg time to new high | 33 days | 12 days |
| Max time to new high | 1067 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
682.58M
Marketcap category
Small-cap
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Employees
294
Website
Investor relations
-
SEC filings
CEO
Ali Tehrani
Country
USA
City
Vancouver
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page